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Clinical trialThe TP53 tumor suppressor gene is mutated in many human tumors, including common types of
cancer such as colon and ovarian cancer. This illustrates the key role of p53 as trigger of cell cycle
arrest or cell death upon oncogenic stress. Most TP53 mutations are missense mutations that result
in single amino acid substitutions in p53 and expression of high levels of dysfunctional p53 protein.
Restoration of wild type p53 function in such tumor cells will induce robust cell death and allow
efﬁcient eradication of the tumor. Therapeutic targeting of mutant p53 in tumors is a rapidly devel-
oping ﬁeld at the forefront of translational cancer research. Various approaches have led to the
identiﬁcation of small molecules that can rescue mutant p53. These include compounds that target
speciﬁc p53 mutations, including PK083 and PK5174 (Y220C mutant p53) and NSC319726 (R175H
mutant p53), as well as PRIMA-1 and its analog APR-246 that affect a wider range of mutant p53
proteins. APR-246 has been tested in a Phase I/II clinical trial with promising results.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).1. Introduction
The TP53 tumor suppressor gene encodes a DNA-binding tran-
scription factor that induces cell growth arrest, senescence and cell
death by apoptosis upon cellular stress [1]. This is achieved by
transcriptional regulation of multiple target genes, including p21
that blocks cell cycle progression and Bax and Puma that promote
apoptosis. Stress as a result of oncogene activation or disruption of
cell cycle control characterizes early stages of tumor evolution.
Oncogenic stress leads to aberrant DNA replication which triggers
a DNA damage response involving activation of ATM, Chk1 and
Chk2 kinases, and p53, and induction of senescence or apoptosis
[2,3]. This p53-dependent response serves to eliminate incipient
tumor cells or otherwise damaged cells. It is now increasingly clear
that p53 is also involved in regulation of various other cellular
processes, for instance metabolism, angiogenesis, and aging.
Importantly, a large fraction of human tumors carry point muta-
tions in TP53 that give rise to single amino acid substitutions in
the p53 protein and disrupt p53 DNA binding (reviewed in [4,5]).
As a consequence, mutant p53-carrying tumor cells are able to
evade apoptosis and senescence, and progress to more malignantvariants. Moreover, since many conventional anticancer agents,
for example cisplatin and doxorubicin, induce DNA damage that
triggers a p53 response, mutation of TP53 is often associated with
enhanced resistance to conventional chemotherapy.
Accumulating evidence demonstrate that TP53 mutations not
only inactivate wild type p53 function but may also confer so
called gain-of-function (GOF) activities to mutant p53 that pro-
mote tumorigenesis (reviewed in [5,6]). This is manifested as a
more aggressive tumor phenotype with increased metastasis in
mice carrying mutant p53 compared to p53 null or wild type mice
[7–9]. At the molecular level, at least one mechanism responsible
for mutant p53 GOF appears to be binding of mutant p53 to other
proteins, including p53 family members p63 and p73 [10]. In the
case of p63, this interaction has been shown to promote integrin
recycling and invasion [11].
The key role of p53 in the cellular response to oncogenic stress,
the fact that p53 is the most frequently mutated gene in cancer, the
high levels of missense mutant p53 expression in many tumors,
and the existence of tumor-promoting GOF activities, all make
p53 a relevant and promising target for therapeutic intervention
in cancer. This has stimulated intense efforts to design drugs for
mutant p53 reactivation in cancer patients. Over the last 15 years,
a number of mutant p53-targeting compounds have been identi-
ﬁed by various strategies. In this review, we shall focus on the most
promising compounds and the clinical development of mutant
p53-reactivating drugs.
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eradication?
Tumors carry multiple genetic alterations which provide critical
functions that characterize cancer cells, the so called Hallmarks of
Cancer [12,13]. From a therapeutic standpoint, this raises the ques-
tion as to howmany genetic alterations in a given tumor that must
be corrected in order to achieve tumor eradication. Speciﬁcally,
what is the effect of restoration of wild type p53 function in a
tumor that has mutant p53? Will p53 reactivation lead to tumor
elimination even if the tumor carries multiple other alterations
in critical cancer genes such as PI-3 kinase, PTEN, Ras or Myc? This
question has been elegantly addressed in vivo. Several studies have
shown that reconstitution of wild type p53 expression by various
means in mice induces rapid tumor regression [14–16]. These
results demonstrate that restoration of wild type p53 expression
is indeed sufﬁcient for elimination of tumors even in the presence
of other tumor-associated genetic alterations. This is presumably
due to the critical role of p53 in the cellular pro-apoptotic or
pro-senescence response to oncogenic stress. Thus, tumors are
addicted to loss of p53 function, and genetic alterations that drive
tumor growth, e.g. activation of Myc or loss of PTEN, may in fact
further enhance p53-dependent cell death upon p53 reconstitution
in a tumor cell context.
3. Small molecules that target mutant p53
One can imagine a number of strategies to target mutant p53 in
tumors. Two approaches for mutant reactivation by small mole-
cules are shown in Fig. 1. In the ﬁrst approach, a mutant p53-bind-
ing molecule restores wild type folding, DNA binding and p53-
dependent transcription, which leads to a biological response and
tumor elimination. In the second approach, disruption of mutant
p53 binding to p53 family proteins p63 and p73 allows p63/p73-
dependent transcription and tumor suppression by several mecha-
nisms. There are also other strategies for targeting mutant p53,
including induction of mutant p53 degradation and inhibition of
downstream signaling pathways (reviewed in [5]).p63/p73mutp53
“wtp53”
Transcripon of p53
target genes
Apoptosis
Senescence
mutp53
p63/p73
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Fig. 1. Two strategies for mutant p53 reactivation. Direct binding of a small
molecule may stabilize the p53 core domain and promote wild type folding, leading
to restoration of speciﬁc DNA binding and transcription of p53 target genes. This
will induce tumor cell apoptosis or senescence. Alternatively, disruption of
complexes between mutant p53 and p53 family members p63 or p73 by a small
molecule may restore p63 and/or p73 function, allowing transcription of p63/p73
target genes and tumor suppression by induction of apoptosis and inhibition of
invasion.In principle, novel targeted drugs can be identiﬁed by rational
design, based on detailed structural knowledge of the drug target,
or random screening of chemical libraries using a suitable assay
with a readout such as induction of cell death. Both strategies have
advantages and disadvantages, and both have been applied in the
case of mutant p53. Further drug development towards the clinic
faces numerous challenges, and should address chemical proper-
ties of hit compounds, including stability, reactivity, solubility
and other aspects related to ‘‘druggability’’, as well as antitumor
efﬁcacy in mouse tumor models.
A rational design approach by Fersht and colleagues has focused
on the Y220C hot spot mutation in p53 which occurs in some
75,000 cases of cancer per year. The Y220C substitution creates a
cavity that destabilizes the p53 protein. Fersht and colleagues
designed Y220C-targeting compounds based on the crystal struc-
ture of the p53 core domain, including PK083 and PK7088. The car-
bazole derivative PK083 binds to the cavity on the p53 surface and
raises the melting temperature of Y220C mutant p53 [17]. Simi-
larly, PK7088 raises the melting temperature of the Y220C mutant,
and was also shown to induce Y220C-dependent cell cycle arrest
and apoptosis in tumor cells [18]. PK7088 promoted correct folding
of Y220 mutant p53 and induced expression of p53 targets p21 and
the Noxa. In addition, PK7088 was shown to trigger nuclear export
of the pro-apoptotic Bax protein to mitochondria, possibly indicat-
ing effects on transcription-independent functions of p53. The
studies on reactivation of Y220C mutant p53 by PK083 and
PK7088 and other compounds raise hopes for efﬁcient targeting
of this mutant in cancer patients. It will be of great interest to
investigate the efﬁcacy of these compounds in animal models
and ultimately in clinical trials.
The compounds PRIMA-1 and APR-246 (PRIMA-1MET) were
identiﬁed using a different approach. Screening of the Diversity
set of 2000 compounds from the National Cancer Institute using
a cell-based assay led to the identiﬁcation of two compounds,
PRIMA-1 [19] and MIRA-1 [20]. PRIMA-1 and the PRIMA-1 analog
PRIMA-1MET, now named APR-246, can restore wild type confor-
mation to mutant p53, induce apoptosis in tumor cells, and inhibit
tumor growth in mice. PRIMA-1 and APR-246 are both converted
to methylene quinuclidinone (MQ), Michael acceptor that can bind
covalently to cysteines in mutant p53 [21]. Importantly, transfer of
MQ-modiﬁed mutant p53 protein into p53 null tumor cells
induced massive apoptosis, indicating that covalent binding of
MQ per se is sufﬁcient to reactivate mutant p53 and induce a p53
biological response.
PRIMA-1 and APR-246 have been shown to inhibit tumor
growth in vitro and in vivo upon systemic administration in vari-
ous tumor types and models. PRIMA-1 was ﬁrst shown to inhibit
growth of osteosarcoma xenografts expressing mutant p53 in SCID
mice [19]. APR-246 inhibited growth of mutant p53-carrying small
cell lung carcinoma (SCLC) cells in vitro and suppressed SCLC
xenograft growth in mice [22]. Other studies have demonstrated
that APR-246 is active against multiple myeloma cells in vitro
and inhibits multiple myeloma tumor growth in mice [23].
MQ can also bind to cysteine residues in wild type p53, and the
binding is increased in unfolded p53 [21]. Consistent with this
ﬁnding, APR-246 was shown to restore the function of inactive
wild type p53 in a three-dimensional collagen gel model of mela-
noma [24]. APR-246 treatment induced expression of pro-apopto-
tic p53 targets Apaf1 and Puma and triggered cell death by
apoptosis. APR-246 also inhibited melanoma xenograft tumors
in vivo in a p53-dependent manner. Similarly, APR-246 showed
dose-dependent cytotoxic and apoptotic effects in AML cell lines
as well as in primary AML patient cells irrespective of p53 status
[25], and induced apoptosis and upregulation of p53 target genes
p21, Puma and Noxa in Ewing sarcoma cells carrying either wild
type or mutant p53 [26]. PRIMA-1 was also shown to signiﬁcantly
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nuclear wild type p53 in a nitrosamine-induced lung cancer model
in mice, suggesting a possible use for this type of compounds in
chemoprevention [27].
As an electrophilic molecule, MQ could potentially bind to cys-
teines in many proteins in cells. However, not all such modiﬁca-
tions will necessarily have cytotoxic effects [21]. Moreover,
cysteine modiﬁcation will be affected by various factors that limit
the number of protein targets, including accessibility of cysteines
to the potential ligand, nucleophilicity of the sulfur atom, and ﬂex-
ibility of the targeted structural domain. Nevertheless, it is likely
that modiﬁcation of speciﬁc proteins by MQ will lead to cytotoxic-
ity. Modiﬁcation of TrxR1 (Thioredoxin reductase 1) by APR-246/
MQ, which converts this enzyme from a reductase to an oxidase
that can induce ROS (reactive oxygen species), may contribute to
APR-246-induced cell death and probably accounts, at least in part,
for the observed effects of APR-246 on p53 null cancer cells [28].
Rieber and Strasberg-Rieber assessed the efﬁcacy of PRIMA-1
under hypoxic conditions and showed that hypoxia enhanced the
sensitivity of SKBR3 breast carcinoma cells carrying mutant p53
to PRIMA-1. Also, combination of PRIMA-1 with peroxidase
increased apoptosis and induction of Puma and Mn-SOD in MCF-
7 breast carcinoma cells overexpressing mutant p53 [29]. Hypoxia
led to increased reactivity with the mutant p53-speciﬁc antibody
PAb240.
These results indicate that the antitumor activity of PRIMA-1 is
inﬂuenced by hypoxia and suggest that PRIMA-1 may be useful for
addressing chemoresistance in hypoxic tumors.
The p53 family proteins p63 and p73 share high sequence
homology with p53 in their DNA binding domains [30]. APR-246
can restore the pro-apoptotic function to mutant TAp63c and
TAp73b in tumor cells and induce expression of the p53/p63/p73
downstream targets p21 and Noxa [31]. Moreover, APR-246 can
rescue mutant p63 in primary adult skin keratinocytes from ectro-
dactyly, ectodermal dysplasia, and cleft lip/palate (EEC) syndrome
patients with p63 mutations. Keratinocytes from these patients
show impaired epidermal differentiation. Treatment with APR-
246 partially rescued morphology and gene expression during epi-
dermal stratiﬁcation, and restored expression of p63-regulated
genes [32]. Also, APR-246 was shown to revert corneal epithelial
lineage commitment and restore a normal p63-related signaling
pathway in induced pluripotent stem cells (iPSC) from EEC patients
carrying two different point mutations in the DNA binding domain
of p63 [33]. The reactivation of mutant forms of p53 family pro-
teins by APR-246 indicates a common mechanism that presumably
involves homologous structural elements in the targeted proteins.
Thus, as shown in Fig. 2, targeting two structurally related proteins
by APR-246 through a similar molecular mechanism leads to
entirely different biological outcomes.mutp53
mutp63
APR-246
Fig. 2. APR-246 targets both mutant p53 and mutant p63. In the case of mutant p53, reac
the tumor. For mutant p63, reactivation by APR-246 in keratinocytes derived from EE
conformational rescue by APR-246 may lead to entirely different biological outcomes inThe maleimide MIRA-1 was identiﬁed along with PRIMA-1 in
our screen of the NCI Diversity set [20]. MIRA-1 and its structural
analogs that contain a reactive carbon–carbon double bond are
capable of mutant reactivation [20]. MIRA-1 analogs that lack the
reactive double bond show no biological mutant p53-dependent
activity, consistent with the notion that Michael acceptor activity
is critical for mutant p53 reactivation. Indeed, other cysteine-tar-
geting compounds have been shown to affect stability of mutant
p53. Kaar et al. [34] identiﬁed a series of compounds containing
an a,b-unsaturated double bond, characteristic of Michael accep-
tors, that can bind covalently to p53 cysteines. Binding was shown
to raise the melting temperature of wild type and hotspot mutant
R175H, Y220C, G245S, R249S, and R282 core domains. Mass spec-
trometry revealed binding to C124 and C141, followed by C135,
C182, C277, C176 and C275. These modiﬁcations reduced p53
DNA binding activity. Modiﬁcation of C277, which is located on
the DNA-binding surface of p53, is probably most critical for this
effect. Other studies have identiﬁed C182 and C277 as preferential
sites for modiﬁcation by N-ethylmaleimide [35].
The compound CP-31398 was identiﬁed as a substance that
protects p53 from thermal denaturation [36]. CP-31398 has anti-
tumor activity in vivo in a transgenic UPII-SV40T mouse model
of bladder transitional cell carcinoma [37]. Also, the compound
has shown strong cancer chemopreventive ability in a nitrosa-
mine-induced lung cancer model [27]. CP-31398 seems to be able
not only reactivate mutant p53 but also induce stabilization of wild
type p53 [38], probably at least in part due to its ability to bind
DNA [39]. CP-31398 has a reactive carbon–carbon double bond
but its activity as Michael acceptor is compromised due to steric
effects of neighboring functional groups [40]. STIMA-1, a low
molecular weight compound and Michael acceptor with some
structural similarity to CP-31398, can enhance mutant p53 DNA
binding and expression of p53 target proteins and induce mutant
p53-dependent apoptosis in human tumor cells [40].
Several other mutant p53-targeting small molecules have been
identiﬁed by various approaches. The small molecule SCH529074
was shown to bind to the core domain of p53 and act as a chaper-
one that restores wild type function [41]. In addition, it inhibits
p53 ubiquitination by Mdm2. Ellipticine [42] and the compound
P53R3 [43] have also been shown to reactivate mutant p53. How-
ever, the molecular mechanisms of action of these compounds
with respect to mutant p53 reactivation are not fully understood
and data on their efﬁcacy in animal models have so far not been
reported.
Molecular modeling may potentially be a fruitful strategy for
identiﬁcation of novel compounds that stabilize and/or refold
p53, but one problem in such studies is the highly ﬂexible struc-
ture of the p53 core domain that prevents reliable predictions of
protein structure behavior in solution and upon ligand binding.Apoptosis
Tumor eliminaon
Diﬀerenaon
tivation by APR-246 in tumor cells triggers cell death by apoptosis which eliminates
C syndrome patients restores p63-dependent differentiation. This illustrates how
different cell types, even if the molecular mechanism is similar.
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ods to identify a transiently open binding pocket between the L1
loop and sheet S3 in the core domain of p53 [44]. The L1/S3 pocket
contains C124, C141 and C135. This particular region is known to
harbor several targets for secondary mutations that reactivate cer-
tain tumor-derived p53 mutants [45,46], thus suggesting its
importance for regulation of p53 folding. Docking simulations
showed that p53-targeting compounds MQ, MIRA-1, 2, and 3,
and STIMA-1, can bind preferentially to the region corresponding
to the L1/S3 pocket in human p53. Introduction of a C124A substi-
tution in R175H mutant p53 abolished the effect of PRIMA-1 in
Saos-2 osteosarcoma cells. Although these results need to be con-
ﬁrmed, they provide interesting clues as to which cysteine residues
in mutant p53 that might be most relevant for conformational res-
cue by PRIMA-1 and APR-246.
The compound NSC319726 speciﬁcally targets R175H mutant
p53 [47]. Analysis of information in NCI’s database indicated that
two compounds from the thiosemicarbazone family increased
growth inhibitory activity in mutant p53-carrying tumor cells,
and in particular for those that carry R175H mutant p53.
NSC319726 was shown to restore wild type structure and function
to R175H mutant p53, induce apoptosis in R175H mutant p53-car-
rying tumor cells, and inhibit growth of R175H mutant p53-carry-
ing tumor xenografts. The mechanism of action of NSC319726 is
not fully understood but seems to depend on the zinc ion-chelating
properties of the compound. These results are consistent with pre-
vious studies showing the importance of zinc for p53 function
(reviewed in [5,48]).
4. Targeting complexes between mutant p53 and other proteins
An alternative approach to targeting mutant p53 itself is disrup-
tion of complex formation between mutant p53 and p63 or p73
(Fig. 1). As mentioned above, mutant p53 may exert gain-of-func-
tion activity by binding and blocking the function of other p53
family proteins. The small molecule RETRA activates p53 target
genes and inhibits mutant p53-carrying tumor cells in vitro and
tumor xenografts in vivo in mice [49]. RETRA induces expression
of p73 and releases p73 from mutant p53 complexes, resulting in
tumor suppression similar to functional reactivation of mutant
p53. RETRA has activity against various p53 mutants and little
effect on normal cells. These results demonstrate that complexes
between mutant p53 and p53 family member p73 are potential
targets for novel anticancer drugs.
5. Exploring combination treatment
Tumor heterogeneity and dynamics pose major difﬁculties for
efﬁcient treatment of cancer. Treatment with targeted anticancer
drugs will inevitably lead to selection for variants that show
increased resistance, for example by loss or mutation of the drug
target. One possible strategy to prevent the emergence of resistant
clones is combination therapy. In the case of the mutant p53-tar-
geting compound APR-246, synergy with chemotherapeutic drugs
including adriamycin and danorubicin has been observed in vitro
and in vivo [23,25,50]. This effect is presumably due to restoration
of wild type p53 activity, which is known to be important for the
response to DNA-damaging anticancer drugs. It is also plausible
that enhanced levels of mutant p53 in tumor cells exposed to
DNA-damaging drugs may increase sensitivity to APR-246. More-
over, combination treatment with mutant p53-targeting molecules
and wild type p53-activating compounds such as Nutlin that
enhance wild type p53 activity by blocking its binding to the
Mdm2 protein (for a review of Nutlin and other compounds that
disrupt p53–Mdm2 binding, see [48]) is an attractive strategy, asit should prevent rapid degradation of p53 upon activation of
Mdm2. Indeed, synergy between PK7088 and Nutlin was observed
[18].
There may also be more unexpected synergies. PRIMA-1 was
shown to restore sensitivity of mutant p53-carrying thyroid tumor
cells to 3-Deazaneplanocin A (DZNep), an inhibitor of histone
methylation [51]. DZNep depletes EZH2, a core component of
the polycomb repressive complex 2 (PRC2), which is overexpres-
sed in many human tumors. While DZNep alone only inhibited
growth of wild type p53 thyroid tumor cells, the combination of
PRIMA-1 and DZNep had potent antitumor effect on mutant
p53-expressing thyroid tumor cells in vitro and in xenograft
tumors in vivo.
6. Targeting non-sense mutant p53 by induction of translation
read-through
Almost 8% of all TP53 mutations in human tumors are non-
sense mutations. The most common non-sense TP53 mutation,
R213X, is in fact one of the 10 most common TP53 mutations over-
all (http://p53.free.fr). Tumors that carry non-sense p53 mutations
lack full length p53 expression but may express low levels of trun-
cated p53. Non-sense mutant mRNA is degraded by non-sense-
mediated RNA decay (NMD). Thus, these tumors are not amenable
to mutant p53 reactivation by the refolding strategies described
above. Previous studies have indicated that aminoglycoside antibi-
otics such as G418 and gentamicin can induce read-through and
restore expression of non-sense mutant p53 and other genes
[52]. However, aminoglycosides are not suitable for long term ther-
apy at the required doses due to severe side effects. Thus, identiﬁ-
cation of novel efﬁcient inducers of read-through of non-sense
mutant p53 is a promising approach for improved treatment of a
signiﬁcant fraction of human tumors. The combination of a read-
through drug and a novel inhibitor of NMD was recently shown
to restore full length p53 expression in tumor cells carrying non-
sense mutant p53 [53].
7. Clinical trials with mutant p53-targeting compounds
Many of the mutant p53-targeting compounds are still at an
early stage of preclinical development. The most advanced is
APR-246 which has been tested in a Phase I/II clinical trial in 22
patients with hematological malignancies or hormone-refractory
prostate cancer [54]. The aims of this ﬁrst-in-man clinical study
were to determine maximum-tolerated dose (MTD), safety, dose-
limiting toxicities, and pharmacokinetics of APR-246. Patients
received 2 h intravenous infusion once per day for 4 days. APR-
246 was well tolerated. The most common adverse effects were
dizziness, fatigue, headache, and confusion. Pharmacokinetics
showed minor interindividual variation and a half-life of 4–5 h.
MTD was deﬁned as 60 mg/kg. Analysis of patient tumor cells
revealed induction of cell cycle arrest, apoptosis, and p53 target
gene expression in several patients upon treatment. Microarray
analysis demonstrated changes in genes that regulate cell growth
and cell death. Clinical effects were observed in two patients.
One AML patient with a p53 core domain mutation (V173M)
showed a marked reduction of bone marrow blasts (46–26%),
and one non-Hodgkin’s lymphoma patient with a p53 splice site
mutation showed a minor clinical response by CT scan. This study
demonstrates that APR-246 is safe at predicted therapeutic plasma
levels, has a favorable pharmacokinetic proﬁle, and can induce
biological effects in tumor cells in vivo that are consistent with
reactivation of p53 as the proposed mechanism of action. The
clinical efﬁcacy of APR-246 should be studied further in Phase II
trials.
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Ambitious efforts to develop pharmacological strategies for
reactivation of p53 in human tumors are underway. Activation of
wild type p53 by disrupting the interaction between p53 and
Mdm2 has been successfully achieved by Nutlin and a range of
other small molecules. Several of these compounds are currently
in clinical trials. Pharmacological rescue of mutant p53 is an even
greater challenge, due to the heterogeneity of mutant p53 proteins
and the need to restore proper folding of a mutant protein, as
opposed to blocking protein–protein interactions or inhibiting
oncogenic kinases. Rational design and random screening
approaches have led to the discovery of a number of small mole-
cules that can reactivate speciﬁc p53 mutant proteins or act more
broadly on various p53 mutants. Other strategies include disrup-
tion of complexes between mutant p53 and p53 family proteins
p63 and p73, and induction of read-through of non-sense muta-
tions in p53. Combination treatment with mutant p53-targeting
compounds and conventional chemotherapeutic drugs, p53–
Mdm2 inhibitors or other compounds has shown promising
synergies. Thus, progress has been impressive and even if many
problems and challenges undoubtedly remain, we are hopefully
getting closer to clinical application of mutant p53-targeting drugs
for treatment of cancer.
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